
Claire E Higham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2834520/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Value of Early Post-Operative Growth Hormone Testing in Predicting Long-Term Remission and Residual Disease after Transsphenoidal Surgery for Acromegaly. Neuroendocrinology, 2022, 112, 345-357.	1.2	5
2	Regulation of bone mass in endocrine diseases including diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101614.	2.2	3
3	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. European Journal of Endocrinology, 2022, 186, P35-P52.	1.9	42
4	RadBone: bone toxicity following pelvic radiotherapy – a prospective randomised controlled feasibility study evaluating a musculoskeletal health package in women with gynaecological cancers undergoing pelvic radiotherapy. BMJ Open, 2022, 12, e056600.	0.8	1
5	Real-World Estimates of Adrenal Insufficiency–Related Adverse Events in Children With Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e192-e203.	1.8	20
6	Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4766-e4775.	1.8	7
7	Safety of growth hormone (CH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors—a review of research and clinical practice. Pituitary, 2021, 24, 810-827.	1.6	17
8	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes and Endocrinology,the, 2021, 9, 622-637.	5.5	29
9	Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 314-326.	1.8	30
10	Outcomes of Patients with Nelson's Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1527-1537.	1.8	26
11	Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women. Journal of the Endocrine Society, 2020, 4, bvz009.	0.1	5
12	Primary epithelialâ€myoepithelial carcinoma of the pituitary gland. Neuropathology, 2020, 40, 261-267.	0.7	4
13	RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer. European Journal of Cancer, 2020, 136, 204-205.	1.3	2
14	Adjuvant immunotherapy: the sting in the tail. European Journal of Cancer, 2020, 132, 207-210.	1.3	20
15	Oestradiol measurement during fulvestrant treatment for breast cancer. British Journal of Cancer, 2019, 120, 404-406.	2.9	18
16	Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. Thyroid, 2019, 29, 1003-1011.	2.4	72
17	Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review. Endocrine Reviews, 2019, 40, 711-767.	8.9	91
18	Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. European Journal of Endocrinology, 2018, 178, 491-499.	1.9	47

Claire E Higham

#	Article	IF	CITATIONS
19	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	1.9	196
20	Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults. The Cochrane Library, 2018, 4, CD010604.	1.5	13
21	Effects of random glucose (Glc) levels on outcomes of patients (pts) with pancreatic ductal adenocarcinoma (PDAC). Annals of Oncology, 2018, 29, viii256.	0.6	1
22	Emergency management of immuneâ€related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes. Cancer, 2018, 124, 4731-4731.	2.0	4
23	SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocrine Connections, 2018, 7, G1-G7.	0.8	97
24	Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (<scp>JBDS</scp>) for Inpatient Care group. Diabetic Medicine, 2018, 35, 1011-1017.	1.2	87
25	Joint British Diabetes Societies for Inpatient Care: clinical guidelines and improving inpatient diabetes care. Diabetic Medicine, 2018, 35, 988-991.	1.2	16
26	Fanconi anemia with sun-sensitivity caused by a Xeroderma pigmentosum-associated missense mutation in XPF. BMC Medical Genetics, 2018, 19, 7.	2.1	9
27	Pituitary hormone replacement. Medicine, 2017, 45, 470-474.	0.2	0
28	Proopiomelanocortin interference in the measurement of adrenocorticotrophic hormone: a United Kingdom National External Quality Assessment Service study. Clinical Endocrinology, 2016, 85, 569-574.	1.2	12
29	Hypopituitarism. Lancet, The, 2016, 388, 2403-2415.	6.3	195
30	GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. European Journal of Endocrinology, 2016, 174, P1-P9.	1.9	184
31	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, .	0.2	60
32	Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E531-E541.	1.8	145
33	Bone Health and Pelvic Radiotherapy. Clinical Oncology, 2015, 27, 668-678.	0.6	49
34	60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-GH axis: the past 60 years. Journal of Endocrinology, 2015, 226, T123-T140.	1.2	58
35	Pituitary hormone replacement. Medicine, 2013, 41, 504-507.	0.2	0
36	Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1187-1193.	1.8	90

Claire E Higham

#	Article	IF	CITATIONS
37	Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly. Obstetrical and Gynecological Survey, 2012, 67, 475-476.	0.2	1
38	Acromegaly surgery in Manchester revisited – The impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clinical Endocrinology, 2012, 76, 399-406.	1.2	57
39	GHR Antagonist: Efficacy and Safety. , 2011, , 339-357.		0
40	Licorice – or more?. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 250-253.	0.6	7
41	Successful use of weekly pegvisomant administration in patients with acromegaly. European Journal of Endocrinology, 2009, 161, 21-25.	1.9	38
42	Pegvisomant Improves Insulin Sensitivity and Reduces Overnight Free Fatty Acid Concentrations in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2459-2463.	1.8	66
43	Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. European Journal of Endocrinology, 2009, 161, 705-713.	1.9	77
44	Pituitary hormone replacement. Medicine, 2009, 37, 399-402.	0.2	0
45	Longâ€ŧerm experience of pegvisomant therapy as a treatment for acromegaly. Clinical Endocrinology, 2009, 71, 86-91.	1.2	62
46	Growth hormone excess and the development of growth hormone receptor antagonists. Experimental Physiology, 2008, 93, 1157-1169.	0.9	30
47	IGF-I measurements in the monitoring of GH therapy. Pituitary, 2007, 10, 159-163.	1.6	16
48	Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis. Journal of Molecular Biology, 2001, 308, 515-525.	2.0	226
49	Processing of synthetic pro-islet amyloid polypeptide (proIAPP) â€~amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. FEBS Journal, 2000, 267, 4998-5004.	0.2	49
50	The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. British Journal of Pharmacology, 2000, 131, 756-760.	2.7	75
51	Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Letters, 2000, 470, 55-60.	1.3	114
52	Formation of amyloid fibrils by peptides derived from the bacterial cold shock protein CspB. Protein Science, 1999, 8, 1350-1357.	3.1	63
53	Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults. The Cochrane Library, 0, , .	1.5	1